Table 1 Patient characteristics before and after propensity matching
Before matching | After matching | |||||
|---|---|---|---|---|---|---|
Ablation (n = 82) | Nonablation (n = 69) | P value | Ablation (n = 43) | Nonablation (n = 43) | P value | |
Age, years | 65.2 ± 8.5 | 70.1 ± 7.6 | < 0.001 | 68.3 ± 7.6 | 68.0 ± 8.4 | 0.851 |
Male, n (%) | 44 (53.7%) | 36 (52.2%) | 0.856 | 20 (46.5%) | 25 (58.1%) | 0.280 |
AF duration, months (median, IQR) | 12.0 (2–48) | 24.0 (4–36) | 0.540 | 12.0 (3–48) | 24.0 (1–36) | 0.447 |
Paroxysmal AF, n (%) | 22 (26.8%) | 14 (20.3%) | 0.348 | 13 (30.2%) | 8 (18.6%) | 0.209 |
Persistent AF, n (%) | 60 (73.2%) | 55 (79.7%) | 30 (69.8%) | 35 (81.4%) | ||
CHA2DS2-VASc score | 2.4 ± 1.6 | 3.5 ± 1.8 | < 0.001 | 3.1 ± 1.6 | 2.9 ± 1.8 | 0.564 |
Diabetes mellitus, n (%) | 13 (15.9%) | 13 (18.8%) | 0.628 | 9 (20.9%) | 9 (20.9%) | 1.000 |
Hypertension, n (%) | 46 (56.1%) | 36 (52.2%) | 0.630 | 24 (55.8%) | 20 (46.5%) | 0.388 |
Previous stroke or TIA, n (%) | 10 (12.2%) | 19 (27.5%) | 0.017 | 9 (20.9%) | 11 (25.6%) | 0.610 |
Heart failure, n (%) | 5 (6.1%) | 4 (5.8%) | 1.000 | 4 (9.3%) | 2 (4.7%) | 0.676 |
Coronary artery disease, n (%) | 19 (23.2%) | 31 (44.9%) | 0.005 | 16 (37.2%) | 12 (27.9%) | 0.357 |
Chronic kidney disease, n (%) | 1 (1.2%) | 7 (10.1%) | 0.024 | 1 (2.3%) | 4 (9.3%) | 0.360 |
Echocardiogram | ||||||
LVEF, % | 58.4 ± 8.1 | 54.1 ± 9.4 | 0.003 | 56.9 ± 9.1 | 55.9 ± 9.3 | 0.599 |
LA diameter, mm | 43.8 ± 4.8 | 46.4 ± 4.7 | 0.001 | 43.1 ± 4.7 | 46.5 ± 4.8 | 0.001 |
LVESD, mm | 33.4 ± 5.8 | 36.3 ± 7.6 | 0.010 | 34.0 ± 6.9 | 35.2 ± 7.2 | 0.409 |
LVEDD, mm | 49.1 ± 5.4 | 50.7 ± 7.6 | 0.138 | 49.1 ± 5.6 | 50.3 ± 7.3 | 0.400 |
Medication use | ||||||
Anticoagulants, n (%) | 60 (73.2%) | 54 (78.3%) | 0.469 | 26 (60.5%) | 29 (67.4%) | 0.500 |
β-blockers, n (%) | 57 (69.5%) | 46 (66.7%) | 0.708 | 32 (74.4%) | 27 (62.8%) | 0.245 |
Antiarrhythmics (Class I or III), n (%) | 34 (41.5%) | 12 (17.4%) | 0.001 | 8 (18.6%) | 7 (16.3%) | 0.776 |
Calcium channel blockers, n (%) | 13 (15.9%) | 13 (18.8%) | 0.628 | 7 (16.3%) | 7 (16.3%) | 1.000 |
Digoxin, n (%) | 16 (19.5%) | 21 (30.4%) | 0.120 | 11 (25.6%) | 9 (20.9%) | 0.610 |
Follow-up, months | 22.4 ± 8.1 | 19.6 ± 9.2 | 0.051 | 22.9 ± 7.9 | 20.1 ± 9.6 | 0.151 |